CN103930094A - 即释4-甲基-3[[4-(3-吡啶基)-2-嘧啶基]氨基]-n-[5-(4-甲基-1h-咪唑-1-基)-3-(三氟甲基)苯基]苯甲酰胺剂型 - Google Patents
即释4-甲基-3[[4-(3-吡啶基)-2-嘧啶基]氨基]-n-[5-(4-甲基-1h-咪唑-1-基)-3-(三氟甲基)苯基]苯甲酰胺剂型 Download PDFInfo
- Publication number
- CN103930094A CN103930094A CN201280055937.8A CN201280055937A CN103930094A CN 103930094 A CN103930094 A CN 103930094A CN 201280055937 A CN201280055937 A CN 201280055937A CN 103930094 A CN103930094 A CN 103930094A
- Authority
- CN
- China
- Prior art keywords
- methyl
- dosage forms
- solid dosage
- amino
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161559281P | 2011-11-14 | 2011-11-14 | |
US61/559,281 | 2011-11-14 | ||
PCT/US2012/064610 WO2013074432A1 (en) | 2011-11-14 | 2012-11-12 | Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103930094A true CN103930094A (zh) | 2014-07-16 |
Family
ID=47324402
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280055937.8A Pending CN103930094A (zh) | 2011-11-14 | 2012-11-12 | 即释4-甲基-3[[4-(3-吡啶基)-2-嘧啶基]氨基]-n-[5-(4-甲基-1h-咪唑-1-基)-3-(三氟甲基)苯基]苯甲酰胺剂型 |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP2779995A1 (es) |
JP (1) | JP6275645B2 (es) |
KR (1) | KR20140093230A (es) |
CN (1) | CN103930094A (es) |
AR (1) | AR088844A1 (es) |
BR (1) | BR112014011518A2 (es) |
CA (1) | CA2855503A1 (es) |
CL (1) | CL2014001247A1 (es) |
CO (1) | CO6960546A2 (es) |
EA (1) | EA201490960A1 (es) |
GT (1) | GT201400094A (es) |
HK (1) | HK1197025A1 (es) |
IL (1) | IL232480A0 (es) |
IN (1) | IN2014DN03416A (es) |
MA (1) | MA35636B1 (es) |
MX (1) | MX2014005874A (es) |
PE (1) | PE20141337A1 (es) |
SG (2) | SG10201707768RA (es) |
TN (1) | TN2014000177A1 (es) |
TW (1) | TWI574690B (es) |
WO (1) | WO2013074432A1 (es) |
ZA (1) | ZA201402756B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2792360A1 (en) | 2013-04-18 | 2014-10-22 | IP Gesellschaft für Management mbH | (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV |
CZ2017821A3 (cs) | 2017-12-20 | 2019-07-03 | Zentiva, K.S. | Léková forma obsahující krystalický nilotinib |
JP7378279B2 (ja) * | 2019-11-18 | 2023-11-13 | 日本化薬株式会社 | ニロチニブを有効成分とする医薬錠剤及びその製造方法 |
JP7489849B2 (ja) | 2020-07-20 | 2024-05-24 | 日本化薬株式会社 | ニロチニブ錠剤 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101516344A (zh) * | 2006-09-27 | 2009-08-26 | 诺瓦提斯公司 | 包含尼罗替尼或其盐的药物组合物 |
US20100136097A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems for modulating inflammation |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0215676D0 (en) * | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
GT200600316A (es) | 2005-07-20 | 2007-04-02 | Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida. | |
GT200600315A (es) | 2005-07-20 | 2007-03-19 | Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida | |
WO2012164578A1 (en) * | 2011-06-02 | 2012-12-06 | Hetero Research Foundation | Compositions and methods for preparing immediate release formulations of nilotinib |
-
2012
- 2012-11-12 SG SG10201707768RA patent/SG10201707768RA/en unknown
- 2012-11-12 WO PCT/US2012/064610 patent/WO2013074432A1/en active Application Filing
- 2012-11-12 SG SG11201401476TA patent/SG11201401476TA/en unknown
- 2012-11-12 MX MX2014005874A patent/MX2014005874A/es unknown
- 2012-11-12 EA EA201490960A patent/EA201490960A1/ru unknown
- 2012-11-12 IN IN3416DEN2014 patent/IN2014DN03416A/en unknown
- 2012-11-12 JP JP2014541363A patent/JP6275645B2/ja not_active Expired - Fee Related
- 2012-11-12 KR KR1020147012521A patent/KR20140093230A/ko not_active Application Discontinuation
- 2012-11-12 EP EP12798500.0A patent/EP2779995A1/en not_active Withdrawn
- 2012-11-12 PE PE2014000672A patent/PE20141337A1/es not_active Application Discontinuation
- 2012-11-12 CA CA2855503A patent/CA2855503A1/en not_active Abandoned
- 2012-11-12 BR BR112014011518A patent/BR112014011518A2/pt not_active IP Right Cessation
- 2012-11-12 CN CN201280055937.8A patent/CN103930094A/zh active Pending
- 2012-11-12 AR ARP120104259A patent/AR088844A1/es unknown
- 2012-11-13 TW TW101142278A patent/TWI574690B/zh not_active IP Right Cessation
-
2014
- 2014-04-15 ZA ZA2014/02756A patent/ZA201402756B/en unknown
- 2014-04-25 TN TNP2014000177A patent/TN2014000177A1/en unknown
- 2014-05-05 IL IL232480A patent/IL232480A0/en unknown
- 2014-05-07 MA MA36991A patent/MA35636B1/fr unknown
- 2014-05-13 CL CL2014001247A patent/CL2014001247A1/es unknown
- 2014-05-14 GT GT201400094A patent/GT201400094A/es unknown
- 2014-05-14 CO CO14103891A patent/CO6960546A2/es unknown
- 2014-10-21 HK HK14110470A patent/HK1197025A1/xx unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101516344A (zh) * | 2006-09-27 | 2009-08-26 | 诺瓦提斯公司 | 包含尼罗替尼或其盐的药物组合物 |
US20100136097A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems for modulating inflammation |
Non-Patent Citations (2)
Title |
---|
L. ZEMA. A.等: "Different HPMC viscosity grades as coating agents for an oral time and/or site-controlled delivery system: An investigation into the mechanisms governing drug release", 《JOURNAL OF PHARMACEUTICAL SCIENCES》 * |
PETER KLEINEBUDDE: "Roll compaction/dry granulation: Pharmaceutical applications", 《EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS》 * |
Also Published As
Publication number | Publication date |
---|---|
CO6960546A2 (es) | 2014-05-30 |
KR20140093230A (ko) | 2014-07-25 |
CL2014001247A1 (es) | 2014-10-17 |
ZA201402756B (en) | 2015-04-29 |
EA201490960A1 (ru) | 2014-08-29 |
GT201400094A (es) | 2017-09-28 |
NZ623844A (en) | 2016-09-30 |
TWI574690B (zh) | 2017-03-21 |
CA2855503A1 (en) | 2013-05-23 |
MX2014005874A (es) | 2014-06-23 |
TN2014000177A1 (en) | 2015-09-30 |
SG11201401476TA (en) | 2014-10-30 |
SG10201707768RA (en) | 2017-10-30 |
AR088844A1 (es) | 2014-07-10 |
BR112014011518A2 (pt) | 2017-05-16 |
TW201325594A (zh) | 2013-07-01 |
AU2012339829A1 (en) | 2014-05-29 |
IL232480A0 (en) | 2014-06-30 |
JP2014533283A (ja) | 2014-12-11 |
IN2014DN03416A (es) | 2015-06-26 |
HK1197025A1 (en) | 2015-01-02 |
MA35636B1 (fr) | 2014-11-01 |
JP6275645B2 (ja) | 2018-02-07 |
PE20141337A1 (es) | 2014-10-16 |
AU2012339829B2 (en) | 2016-05-12 |
EP2779995A1 (en) | 2014-09-24 |
WO2013074432A1 (en) | 2013-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103608342A (zh) | 使用有机酸作为助溶剂的4-甲基-3-[[4-(3-吡啶基)-2-嘧啶基]氨基]-n-[5-(4-甲基-1h-咪唑-1-基)-3-(三氟甲基)苯基]苯甲酰胺的修饰释放制剂 | |
US10786507B2 (en) | Pharmaceutical composition containing JAK kinase inhibitor or pharmaceutically acceptable salt thereof | |
ES2587912T3 (es) | Composición farmacéutica que comprende olmesartán medoxomilo y rosuvastatina o su sal | |
US20130122093A1 (en) | Formulations of a src/abl inhibitor | |
US20120171296A1 (en) | Rapidly disintegrating solid preparation | |
CN104306350A (zh) | 包含尼罗替尼或其盐的药物组合物 | |
CN1984661A (zh) | 含有伐地那非的控制释放活性成分的制剂 | |
MX2007014454A (es) | Tableta de bosentan dispersable. | |
WO2006040779A2 (en) | Controlled release gastric floating matrix formulation containing imatinib | |
CN103930094A (zh) | 即释4-甲基-3[[4-(3-吡啶基)-2-嘧啶基]氨基]-n-[5-(4-甲基-1h-咪唑-1-基)-3-(三氟甲基)苯基]苯甲酰胺剂型 | |
US9301957B2 (en) | Immediate release 4-methyl-3-4[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-YL)-3-(trifluoromethyl)phenyl] benzamide formulation | |
US9675551B2 (en) | Sublingual pharmaceutical composition containing an antihistamine agent and method for the preparation thereof | |
US10722469B2 (en) | Method for preparing pharmaceutical composition comprising quinoline derivative or salt thereof | |
CN102740855B (zh) | 缓释制剂 | |
US20100272800A1 (en) | Orally disintegrating olanzapine tablet | |
WO2018001569A1 (en) | Pharmaceutical composition comprising a non-purine selective inhibitor of xanthine oxidase and method for the preparation thereof | |
AU2012339829B8 (en) | Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation | |
NZ623844B2 (en) | Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation | |
AU2012271746A1 (en) | Modified release of 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl) benzamide solubilized using organic acids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140716 |
|
WD01 | Invention patent application deemed withdrawn after publication |